JP2016506371A - ヌクレオシドプロドラッグを調製する方法 - Google Patents

ヌクレオシドプロドラッグを調製する方法 Download PDF

Info

Publication number
JP2016506371A
JP2016506371A JP2015542357A JP2015542357A JP2016506371A JP 2016506371 A JP2016506371 A JP 2016506371A JP 2015542357 A JP2015542357 A JP 2015542357A JP 2015542357 A JP2015542357 A JP 2015542357A JP 2016506371 A JP2016506371 A JP 2016506371A
Authority
JP
Japan
Prior art keywords
group
alkyl
formula
product
otf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542357A
Other languages
English (en)
Japanese (ja)
Inventor
マクギガン，クリストファー
ペルトウサティ，ファブリジオ
Original Assignee
ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド
ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016506371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド, ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド filed Critical ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド
Publication of JP2016506371A publication Critical patent/JP2016506371A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
JP2015542357A 2012-11-16 2013-11-15 ヌクレオシドプロドラッグを調製する方法 Pending JP2016506371A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1220666.0 2012-11-16
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
GB1307314.3 2013-04-23
PCT/GB2013/053018 WO2014076490A1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017154931A Division JP2018009000A (ja) 2012-11-16 2017-08-10 ヌクレオシドプロドラッグを調製する方法

Publications (1)

Publication Number Publication Date
JP2016506371A true JP2016506371A (ja) 2016-03-03

Family

ID=49622844

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015542357A Pending JP2016506371A (ja) 2012-11-16 2013-11-15 ヌクレオシドプロドラッグを調製する方法
JP2017154931A Withdrawn JP2018009000A (ja) 2012-11-16 2017-08-10 ヌクレオシドプロドラッグを調製する方法
JP2019112739A Pending JP2019196360A (ja) 2012-11-16 2019-06-18 ヌクレオシドプロドラッグを調製する方法
JP2020171815A Active JP7519259B2 (ja) 2012-11-16 2020-10-12 ヌクレオシドプロドラッグを調製する方法
JP2023007007A Withdrawn JP2023052536A (ja) 2012-11-16 2023-01-20 ヌクレオシドプロドラッグを調製する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017154931A Withdrawn JP2018009000A (ja) 2012-11-16 2017-08-10 ヌクレオシドプロドラッグを調製する方法
JP2019112739A Pending JP2019196360A (ja) 2012-11-16 2019-06-18 ヌクレオシドプロドラッグを調製する方法
JP2020171815A Active JP7519259B2 (ja) 2012-11-16 2020-10-12 ヌクレオシドプロドラッグを調製する方法
JP2023007007A Withdrawn JP2023052536A (ja) 2012-11-16 2023-01-20 ヌクレオシドプロドラッグを調製する方法

Country Status (28)

Country Link
US (3) US10005810B2 (cg-RX-API-DMAC7.html)
EP (3) EP3150616B1 (cg-RX-API-DMAC7.html)
JP (5) JP2016506371A (cg-RX-API-DMAC7.html)
KR (1) KR20150103669A (cg-RX-API-DMAC7.html)
CN (2) CN111592577A (cg-RX-API-DMAC7.html)
AU (1) AU2013346515B2 (cg-RX-API-DMAC7.html)
CA (1) CA2891266C (cg-RX-API-DMAC7.html)
CL (1) CL2015001307A1 (cg-RX-API-DMAC7.html)
CY (2) CY1119161T1 (cg-RX-API-DMAC7.html)
DK (2) DK3150616T3 (cg-RX-API-DMAC7.html)
EA (1) EA028871B1 (cg-RX-API-DMAC7.html)
ES (3) ES2725491T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20170791T1 (cg-RX-API-DMAC7.html)
HU (2) HUE033335T2 (cg-RX-API-DMAC7.html)
IL (1) IL238792A (cg-RX-API-DMAC7.html)
IN (1) IN2015DN04090A (cg-RX-API-DMAC7.html)
LT (2) LT3150616T (cg-RX-API-DMAC7.html)
MX (1) MX374779B (cg-RX-API-DMAC7.html)
MY (1) MY176133A (cg-RX-API-DMAC7.html)
NZ (1) NZ708177A (cg-RX-API-DMAC7.html)
PH (1) PH12015501090B1 (cg-RX-API-DMAC7.html)
PL (2) PL3150616T3 (cg-RX-API-DMAC7.html)
PT (2) PT3235824T (cg-RX-API-DMAC7.html)
RS (2) RS56038B1 (cg-RX-API-DMAC7.html)
SG (3) SG11201503750YA (cg-RX-API-DMAC7.html)
SI (2) SI3235824T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201900341T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014076490A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538341A (ja) * 2015-12-23 2018-12-27 ニューカナ パブリック リミテッド カンパニー 結晶形のゲムシタビン
JP2019522003A (ja) * 2016-07-20 2019-08-08 オプティマス ドラッグズ プライベート リミテッド ソホスブビルの調製のための改善された製造方法
JP2019196360A (ja) * 2012-11-16 2019-11-14 ヌカナ ピーエルシー ヌクレオシドプロドラッグを調製する方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
CA2931458A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
RS56752B1 (sr) 2014-06-25 2018-04-30 NuCana plc Formulacija koja sadrži gemcitabin-prolek
CA2945938C (en) * 2014-06-25 2023-04-18 Nucana Biomed Limited Gemcitabine prodrugs
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
ES2830784T3 (es) 2014-07-22 2021-06-04 NuCana plc Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
AU2015295274A1 (en) * 2014-07-31 2017-01-12 Sandoz Ag Synthesis of phosphoramidates
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
EP4667053A2 (en) 2015-03-06 2025-12-24 ATEA Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2016151542A1 (en) 2015-03-26 2016-09-29 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106539810B (zh) * 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
CN108135920A (zh) * 2015-10-05 2018-06-08 努卡那有限公司 组合疗法
WO2017090264A1 (ja) * 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
HRP20211812T1 (hr) * 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018019188A1 (zh) * 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
SMT202200072T1 (it) 2016-09-07 2022-03-21 Atea Pharmaceuticals Inc Nucleotidi purinici 2'-sostituiti-n6-sostituiti per il trattamento dei virus rna
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN109863160B (zh) * 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
FI3577124T3 (fi) 2017-02-01 2025-02-13 Atea Pharmaceuticals Inc Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
US11186599B2 (en) 2018-06-12 2021-11-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123672A1 (en) * 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
WO2012012465A1 (en) * 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
JP2012514657A (ja) * 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
ATE212661T1 (de) 1998-01-23 2002-02-15 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO2003068162A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
EP1928475B1 (en) * 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2012040127A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US8772474B2 (en) * 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
ES2569185T3 (es) * 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
EP2765997A4 (en) * 2011-10-14 2015-06-24 Stc Unm POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR
HUE033335T2 (en) 2012-11-16 2017-11-28 Univ College Cardiff Consultants Ltd Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
WO2014209979A1 (en) * 2013-06-26 2014-12-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
JP6562908B2 (ja) * 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
JP2016538306A (ja) * 2013-11-27 2016-12-08 アメリカ合衆国 複素環化合物及びその使用方法
CA2931458A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
RS56752B1 (sr) 2014-06-25 2018-04-30 NuCana plc Formulacija koja sadrži gemcitabin-prolek
CA2945938C (en) 2014-06-25 2023-04-18 Nucana Biomed Limited Gemcitabine prodrugs
ES2830784T3 (es) 2014-07-22 2021-06-04 NuCana plc Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
DK3197456T3 (en) 2015-05-14 2018-06-06 NuCana plc CANCER TREATMENTS
CN108135920A (zh) 2015-10-05 2018-06-08 努卡那有限公司 组合疗法
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
EP3738595A1 (en) 2015-12-23 2020-11-18 Nucana PLC Combination therapy
CA3008769A1 (en) 2015-12-23 2017-06-29 NuCana plc Combination therapy comprising nuc-1031 and cisplatin
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy
JP2020171815A (ja) * 2020-07-29 2020-10-22 株式会社ユニバーサルエンターテインメント プログラム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012514657A (ja) * 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
WO2011123672A1 (en) * 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
WO2012012465A1 (en) * 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF ORGANIC CHEMISTRY, vol. 76, no. 20, JPN6017016212, 2011, pages 8311 - 8319, ISSN: 0003553764 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019196360A (ja) * 2012-11-16 2019-11-14 ヌカナ ピーエルシー ヌクレオシドプロドラッグを調製する方法
JP2018538341A (ja) * 2015-12-23 2018-12-27 ニューカナ パブリック リミテッド カンパニー 結晶形のゲムシタビン
JP2019522003A (ja) * 2016-07-20 2019-08-08 オプティマス ドラッグズ プライベート リミテッド ソホスブビルの調製のための改善された製造方法
JP7004480B2 (ja) 2016-07-20 2022-01-21 オプティマス ドラッグズ プライベート リミテッド ソホスブビルの調製のための改善された製造方法

Also Published As

Publication number Publication date
PT3150616T (pt) 2017-06-09
SI3150616T1 (sl) 2017-08-31
PL3150616T3 (pl) 2017-09-29
PT3235824T (pt) 2019-05-30
LT3235824T (lt) 2019-07-10
US11040997B2 (en) 2021-06-22
CA2891266A1 (en) 2014-05-22
JP2023052536A (ja) 2023-04-11
IN2015DN04090A (cg-RX-API-DMAC7.html) 2015-10-09
PH12015501090B1 (en) 2019-01-30
ES2618732T3 (es) 2017-06-22
HUE033335T2 (en) 2017-11-28
CA2891266C (en) 2020-12-08
EA201590955A1 (ru) 2015-08-31
BR112015011155A2 (pt) 2017-07-11
SMT201900341T1 (it) 2019-07-11
US20150291650A1 (en) 2015-10-15
US10005810B2 (en) 2018-06-26
JP7519259B2 (ja) 2024-07-19
JP2019196360A (ja) 2019-11-14
NZ708177A (en) 2017-08-25
AU2013346515B2 (en) 2017-05-25
MX2015006195A (es) 2015-12-08
PH12015501090A1 (en) 2015-07-27
CN104903339A (zh) 2015-09-09
SG10201510324YA (en) 2016-01-28
EP2920192B1 (en) 2017-02-22
SG10201510322UA (en) 2016-01-28
ES2725491T3 (es) 2019-09-24
JP2021020919A (ja) 2021-02-18
EP3235824B1 (en) 2019-03-27
KR20150103669A (ko) 2015-09-11
HRP20190831T1 (hr) 2019-08-23
HK1210784A1 (en) 2016-05-06
AU2013346515A1 (en) 2015-06-04
EP3150616A1 (en) 2017-04-05
SI3235824T1 (sl) 2019-08-30
SMT201700349T1 (it) 2017-09-07
RS58849B1 (sr) 2019-07-31
CL2015001307A1 (es) 2015-12-11
CY1119161T1 (el) 2018-02-14
US20220033433A1 (en) 2022-02-03
EP3235824A1 (en) 2017-10-25
RS56038B1 (sr) 2017-09-29
JP2018009000A (ja) 2018-01-18
HRP20170791T1 (hr) 2017-08-25
DK3150616T3 (en) 2017-06-06
CN111592577A (zh) 2020-08-28
EP3150616B1 (en) 2017-05-10
IL238792A0 (en) 2015-06-30
LT3150616T (lt) 2017-07-25
EA028871B1 (ru) 2018-01-31
IL238792A (en) 2017-09-28
DK3235824T3 (da) 2019-05-20
HUE044605T2 (hu) 2019-11-28
PL3235824T3 (pl) 2019-09-30
WO2014076490A1 (en) 2014-05-22
EP2920192A1 (en) 2015-09-23
SG11201503750YA (en) 2015-06-29
ES2627195T3 (es) 2017-07-27
MX374779B (es) 2025-03-06
US20180273575A1 (en) 2018-09-27
CY1121663T1 (el) 2020-07-31
MY176133A (en) 2020-07-24

Similar Documents

Publication Publication Date Title
JP7519259B2 (ja) ヌクレオシドプロドラッグを調製する方法
JP5271913B2 (ja) 化合物
EP2609923B1 (en) Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
EP2552930A2 (en) Nucleoside phosphoramidates
AU2011235112A1 (en) Nucleoside phosphoramidates
WO2010030858A1 (en) 4'-allene-substituted nucleoside derivatives
HK1230204A1 (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
HK1230204B (en) Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
HK1210784B (en) Process for preparing nucleoside prodrugs
BR112015011155B1 (pt) Composição farmacêutica compreendendo uma mistura de rp/sp gemcitabina-[fenil- benziloxi-1- alaninil)]-fosfato
HK1182938B (en) Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
HK1182938A (en) Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109